Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America: Meaningful improvements in survival

Pasi A. Jänne, Boris Freidlin, Scott Saxman, David H. Johnson, Robert B. Livingston, Frances A. Shepherd, Bruce E. Johnson

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

BACKGROUND. To determine the changes in clinical trials and outcomes of patients with limited-stage small cell lung carcinoma (SCLC) treated on Phase III randomized trials initiated in North America between 1972 and 1992. METHODS. Phase III trials from 1972 to 1992 for patients with limited-stage SCLC were identified. Patients with limited-stage SCLC treated during a similar time interval were also evaluated in the Surveillance, Epidemiology, and End Results (SEER) database. Trends were tested in the number of trials, in the number and gender of patients entered on trial, and in survival duration over time. RESULTS. Thirty trials involving 6564 patients were eligible for analyses. Nineteen trials (61%) involving 3626 patients were initiated within the first half of this time period (1972-1981). The median of median survival times of all patients treated on the control arms of the Phase III trials initiated between 1972 and 1981 and between 1982 and 1992 were 12.0 months (range, 10-16 months) and 17.0 months (range, 11-20 months), respectively (P < 0.001). Of 26 studies available for survival analysis, 5 (19%) showed a statistically significant survival prolongation in the experimental arm compared with the control arm with a median prolongation of 3.4 months (range, 1-5.2 months). All five evaluated some aspect of thoracic radiation therapy. Over a similar time period, there was a 6.4-month increase in the median survival of limited-stage SCLC patients listed in the SEER database (P < 0.0001) and a more than doubling of the 5-year survival from 5.2% to 12.1% (P = 0.0001). CONCLUSIONS. Analyses of the patients with limited-stage SCLC treated on Phase III trials in North America initiated between 1972 and 1992 and those listed in the SEER database show significant improvements in median survivals. Furthermore, the 5-year survival of patients with limited-stage SCLC listed in the SEER database has more than doubled over the last 25 years. Further research will be needed to determine the relative contribution of improved therapy, supportive care, and stage migration to this prolongation in survival.

Original languageEnglish (US)
Pages (from-to)1528-1538
Number of pages11
JournalCancer
Volume95
Issue number7
DOIs
StatePublished - Oct 1 2002

Fingerprint

Small Cell Lung Carcinoma
North America
Survival
Research
Epidemiology
Databases
Survival Analysis
Radiotherapy
Thorax
Clinical Trials

Keywords

  • Limited stage
  • Lung neoplasm
  • Randomized
  • Small cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America : Meaningful improvements in survival. / Jänne, Pasi A.; Freidlin, Boris; Saxman, Scott; Johnson, David H.; Livingston, Robert B.; Shepherd, Frances A.; Johnson, Bruce E.

In: Cancer, Vol. 95, No. 7, 01.10.2002, p. 1528-1538.

Research output: Contribution to journalArticle

Jänne, Pasi A. ; Freidlin, Boris ; Saxman, Scott ; Johnson, David H. ; Livingston, Robert B. ; Shepherd, Frances A. ; Johnson, Bruce E. / Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America : Meaningful improvements in survival. In: Cancer. 2002 ; Vol. 95, No. 7. pp. 1528-1538.
@article{ba902ae1233f4410b255b6ccb582ea67,
title = "Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America: Meaningful improvements in survival",
abstract = "BACKGROUND. To determine the changes in clinical trials and outcomes of patients with limited-stage small cell lung carcinoma (SCLC) treated on Phase III randomized trials initiated in North America between 1972 and 1992. METHODS. Phase III trials from 1972 to 1992 for patients with limited-stage SCLC were identified. Patients with limited-stage SCLC treated during a similar time interval were also evaluated in the Surveillance, Epidemiology, and End Results (SEER) database. Trends were tested in the number of trials, in the number and gender of patients entered on trial, and in survival duration over time. RESULTS. Thirty trials involving 6564 patients were eligible for analyses. Nineteen trials (61{\%}) involving 3626 patients were initiated within the first half of this time period (1972-1981). The median of median survival times of all patients treated on the control arms of the Phase III trials initiated between 1972 and 1981 and between 1982 and 1992 were 12.0 months (range, 10-16 months) and 17.0 months (range, 11-20 months), respectively (P < 0.001). Of 26 studies available for survival analysis, 5 (19{\%}) showed a statistically significant survival prolongation in the experimental arm compared with the control arm with a median prolongation of 3.4 months (range, 1-5.2 months). All five evaluated some aspect of thoracic radiation therapy. Over a similar time period, there was a 6.4-month increase in the median survival of limited-stage SCLC patients listed in the SEER database (P < 0.0001) and a more than doubling of the 5-year survival from 5.2{\%} to 12.1{\%} (P = 0.0001). CONCLUSIONS. Analyses of the patients with limited-stage SCLC treated on Phase III trials in North America initiated between 1972 and 1992 and those listed in the SEER database show significant improvements in median survivals. Furthermore, the 5-year survival of patients with limited-stage SCLC listed in the SEER database has more than doubled over the last 25 years. Further research will be needed to determine the relative contribution of improved therapy, supportive care, and stage migration to this prolongation in survival.",
keywords = "Limited stage, Lung neoplasm, Randomized, Small cell lung carcinoma",
author = "J{\"a}nne, {Pasi A.} and Boris Freidlin and Scott Saxman and Johnson, {David H.} and Livingston, {Robert B.} and Shepherd, {Frances A.} and Johnson, {Bruce E.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1002/cncr.10841",
language = "English (US)",
volume = "95",
pages = "1528--1538",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

T2 - Meaningful improvements in survival

AU - Jänne, Pasi A.

AU - Freidlin, Boris

AU - Saxman, Scott

AU - Johnson, David H.

AU - Livingston, Robert B.

AU - Shepherd, Frances A.

AU - Johnson, Bruce E.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - BACKGROUND. To determine the changes in clinical trials and outcomes of patients with limited-stage small cell lung carcinoma (SCLC) treated on Phase III randomized trials initiated in North America between 1972 and 1992. METHODS. Phase III trials from 1972 to 1992 for patients with limited-stage SCLC were identified. Patients with limited-stage SCLC treated during a similar time interval were also evaluated in the Surveillance, Epidemiology, and End Results (SEER) database. Trends were tested in the number of trials, in the number and gender of patients entered on trial, and in survival duration over time. RESULTS. Thirty trials involving 6564 patients were eligible for analyses. Nineteen trials (61%) involving 3626 patients were initiated within the first half of this time period (1972-1981). The median of median survival times of all patients treated on the control arms of the Phase III trials initiated between 1972 and 1981 and between 1982 and 1992 were 12.0 months (range, 10-16 months) and 17.0 months (range, 11-20 months), respectively (P < 0.001). Of 26 studies available for survival analysis, 5 (19%) showed a statistically significant survival prolongation in the experimental arm compared with the control arm with a median prolongation of 3.4 months (range, 1-5.2 months). All five evaluated some aspect of thoracic radiation therapy. Over a similar time period, there was a 6.4-month increase in the median survival of limited-stage SCLC patients listed in the SEER database (P < 0.0001) and a more than doubling of the 5-year survival from 5.2% to 12.1% (P = 0.0001). CONCLUSIONS. Analyses of the patients with limited-stage SCLC treated on Phase III trials in North America initiated between 1972 and 1992 and those listed in the SEER database show significant improvements in median survivals. Furthermore, the 5-year survival of patients with limited-stage SCLC listed in the SEER database has more than doubled over the last 25 years. Further research will be needed to determine the relative contribution of improved therapy, supportive care, and stage migration to this prolongation in survival.

AB - BACKGROUND. To determine the changes in clinical trials and outcomes of patients with limited-stage small cell lung carcinoma (SCLC) treated on Phase III randomized trials initiated in North America between 1972 and 1992. METHODS. Phase III trials from 1972 to 1992 for patients with limited-stage SCLC were identified. Patients with limited-stage SCLC treated during a similar time interval were also evaluated in the Surveillance, Epidemiology, and End Results (SEER) database. Trends were tested in the number of trials, in the number and gender of patients entered on trial, and in survival duration over time. RESULTS. Thirty trials involving 6564 patients were eligible for analyses. Nineteen trials (61%) involving 3626 patients were initiated within the first half of this time period (1972-1981). The median of median survival times of all patients treated on the control arms of the Phase III trials initiated between 1972 and 1981 and between 1982 and 1992 were 12.0 months (range, 10-16 months) and 17.0 months (range, 11-20 months), respectively (P < 0.001). Of 26 studies available for survival analysis, 5 (19%) showed a statistically significant survival prolongation in the experimental arm compared with the control arm with a median prolongation of 3.4 months (range, 1-5.2 months). All five evaluated some aspect of thoracic radiation therapy. Over a similar time period, there was a 6.4-month increase in the median survival of limited-stage SCLC patients listed in the SEER database (P < 0.0001) and a more than doubling of the 5-year survival from 5.2% to 12.1% (P = 0.0001). CONCLUSIONS. Analyses of the patients with limited-stage SCLC treated on Phase III trials in North America initiated between 1972 and 1992 and those listed in the SEER database show significant improvements in median survivals. Furthermore, the 5-year survival of patients with limited-stage SCLC listed in the SEER database has more than doubled over the last 25 years. Further research will be needed to determine the relative contribution of improved therapy, supportive care, and stage migration to this prolongation in survival.

KW - Limited stage

KW - Lung neoplasm

KW - Randomized

KW - Small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036785452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036785452&partnerID=8YFLogxK

U2 - 10.1002/cncr.10841

DO - 10.1002/cncr.10841

M3 - Article

C2 - 12237922

AN - SCOPUS:0036785452

VL - 95

SP - 1528

EP - 1538

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -